Evidence map›Paper›PMID 30677471›Full record

ArticleInternational journal of radiation oncology, biology, physics2019

Definitive Radiation for Stage I Lung Cancer in a Screened Population: Results From the I-ELCAP.

Eva Berlin, Michael Buckstein, Rowena Yip, David F Yankelevitz, Kenneth Rosenzweig, Claudia I Henschke, I-ELCAP Investigators

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Eva BerlinIcahn School of Medicine at Mount Sinai, New York, New York.
Michael BucksteinDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Rowena YipDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York.
David F YankelevitzDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York.
Kenneth RosenzweigDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Claudia I HenschkeDepartment of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: Claudia.Henschke@mountsinai.org.
I-ELCAP Investigators
Icahn School of Medicine at Mount Sinai · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe International Early Lung Cancer Action Program is a cohort study to assess the cure rate of participants undergoing annual low-dose computed tomography screening for lung cancer. This study compares the characteristics and outcomes of patients who received a diagnosis of clinical stage I non-small cell lung carcinoma (NSCLC) treated with definitive radiation therapy and surgical resection. METHODS AND MATERIALS: Patient information was drawn from the International Early Lung Cancer Action Program database from 1992 to 2017. All instances in which treatment was performed for histologically proven stage I NSCLC using definitive radiation therapy and surgery were identified. The home institution determined radiation plans. Patient characteristics and Kaplan-Meier lung cancer-specific (LCS) long-term survival rates were compared for both types of treatment. Follow-up time was calculated from time of diagnosis until death from lung cancer, loss to follow-up, or December 31, 2017, whichever came earlier.

resultsAmong 82,628 baseline and 109,250 annual repeat screenings, 853 patients received a diagnosis of clinical stage I NSCLC, of whom 31 (3.6%) were treated by definitive radiation therapy and 702 (82.3%) by surgical resection alone. Radiation therapy prescription information was obtainable for 24 of the 31 patients: The median dose was 54.5 Gy, the median number of fractions was 5, and 17 patients were treated using stereotactic body radiation therapy. LCS survival rates were not significantly different for radiation therapy compared with surgery: 90.0% (95% confidence interval, 84.9%-100.0%) versus 94.8% (95% confidence interval, 93.0%-96.6%) (P = .09). Median follow-up time was 9.7 years for all, but it was shorter for those treated by radiation therapy than for those who underwent surgery (4.3 vs 10.0 years, P < .0001).

conclusionsThe majority of patients identified by computed tomography screening were treated with surgical resection. Despite being older and having more comorbidities, LCS long-term survival rates of patients treated with definitive radiation therapy were not significantly different compared with survival rates of patients treated with surgery alone. Radiation therapy appears to be a viable alternative to surgery for screen-diagnosed patients with lung cancer.

Indexed as

AgedCarcinoma, Non-Small-Cell LungConfidence IntervalsFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingRadiotherapy DosageSurvival RateTomography, X-Ray Computed

Identifiers

PMID30677471
OpenAlexW2912982297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.